[Clinical investigation of intratumoral OK-432 administration].
The clinical effect of intratumoral administration of OK-432 was evaluated. The patients with nonresectable advanced cancer were divided into three groups according to administration method of OK-432 at laparotomy: Group I; Intratumoral administration, Group II; Scattering to the abdominal cavity, and Group III; No OK-432, administration. Improvement in suppression of tumor progression was more frequently noticed in the Group I compared to the Group II and III, but there was no significant difference in terms of survival time and rate among the three groups.
D000230:Adenocarcinoma / Q000628:therapy*; D000368:Aged; D001688:Biological Products / Q000008:administration & dosage*; D005773:Gastroscopy / Q000379:methods; D006801:Humans; D007430:Intraoperative Care; D008113:Liver Neoplasms / Q000601:surgery / Q000628:therapy; D008297:Male; D010844:Picibanil / Q000008:administration & dosage*; D013274:Stomach Neoplasms / Q000628:therapy*
D001688:Biological Products; D010844:Picibanil